Following the results of the ORAL Surveillance trial, which demonstrated increased rates of adverse events in people taking JAK inhibitors, Victoria Ruffing provides guidance on how to talk to patients about the risks associated with these medications (6:42).
View more on Medicine Matters rheumatology: bit.ly/2U6Vxhi
26 июл 2024
